Results 51 to 60 of about 8,953 (196)
Allergy, EarlyView.Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton +19 more
wiley +1 more source
Pemphigoid vegetans in childhood: A case report and short review of literature
Indian Journal of Dermatology, 2015 Pemphigoid vegetans is a very rare type of bullous pemphigoid which usually affects the elderly and has not been reported in children. It shows a clinical resemblance to pemphigus vegetans but has distinct histological and immunopathological features of ...
Yasmeen Khatib +3 more
doaj +1 more source
Frontiers in Immunology, 2022 Autoimmune bullous diseases (AIBDs), presenting cutaneous and/or mucosal bullous lesions, are classified into pemphigus and pemphigoid diseases. A longtime observation for complicated AIBD cases is rarely reported.
Hua Qian +9 more
doaj +1 more source
Emerging Paediatric Uses of Dupilumab Beyond Approvals
Clinical &Experimental Allergy, EarlyView.Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese +11 more
wiley +1 more source
Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He +11 more
wiley +1 more source
Effect and length of doxycycline administration in elderly patients with bullous pemphigoid
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease and primarily affects the elderly. Systemic corticosteroids and immunosuppressive drugs are the standard treatment, but side effects often restrict their use. Doxycycline has been proposed as an alternative, but there is limited long‐term, real‐world data on its
Alena Merkel‐Ropele +2 more
wiley +1 more source
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
Acta Dermato-VenereologicaDrug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes.
Dana Shalmon +7 more
doaj +1 more source
Interventions for bullous pemphigoid [PDF]
Cochrane Database of Systematic Reviews, 2003 Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Oral steroids are the standard treatment.This is an update of the review published in 2005.To assess treatments for bullous pemphigoid.In August 2010 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled ...
Khumalo, N. +5 more
openaire +7 more sources
A Case of Oropharyngeal Bullous Pemphigoid Presenting with Haemoptysis
Case Reports in Otolaryngology, 2015 Objective. Bullous pemphigoid is well known for its cutaneous features; however in rare cases it may present with mucosal involvement. We report a case of bullous pemphigoid presenting with haemoptysis, initially presenting to the Ear, Nose and Throat ...
C. M. Lee +2 more
doaj +1 more source